In the healthcare sector, stocks that stand out are typically industry leaders that have proven their market dominance and sustainable growth capabilities. These companies span various subsectors such as biotechnology, pharmaceuticals, and medical devices, and their stocks are considered worthwhile long-term investments, offering investors the potential to benefit steadily from their robust business performance.
Eli Lilly and Company (LLY), a major pharmaceutical player, boasts a product portfolio covering multiple therapeutic areas. In recent years, its weight-loss drug portfolio has become a key driver of rapid revenue growth. Its product tirzepatide, marketed as Mounjaro for type 2 diabetes and as Zepbound for weight loss, is widely used in practice for weight management. Recently, Eli Lilly submitted an application for regulatory approval of an oral weight-loss drug candidate. If successful, this could add an important new member to its product line, as oral formulations offer potential advantages in convenience and production costs over injection pens. Eli Lilly’s weight-loss drugs continue to fuel strong performance, with revenue surging over 50% in the latest quarter. Sales of Mounjaro and Zepbound alone reached approximately $10 billion. Given the high demand for weight-loss medications, the growth outlook for its portfolio remains optimistic for the coming years, which may continue to attract investor attention.
Intuitive Surgical (ISRG) is a global leader in robotic surgery, and its competitive advantages have built a deep economic moat. This is primarily based on two factors: most surgeons are trained on its da Vinci Surgical System and prefer using a familiar platform, while hospitals’ initial investment in the system often exceeds a million dollars, making long-term usage more cost-effective than switching systems. These factors collectively drive continuous growth in system installations, procedure volumes, and company revenue. Notably, the sale of the da Vinci system is not a one-time revenue event; it opens up an ongoing revenue stream, as hospitals require regular maintenance services and consume specialized instruments and accessories with each procedure. In fact, accessories and instruments contribute the majority of Intuitive Surgical’s quarterly revenue. This business model is expected to support the company’s long-term profit growth and stock performance.
Vertex Pharmaceuticals (VRTX) is the global leader in cystic fibrosis (CF) treatment, a position that has strongly driven its earnings and stock price growth in recent years. Its intellectual property is expected to maintain its advantage in this area until the end of the decade, and the company continues to innovate within the field. Vertex’s CF drugs are all blockbuster products with annual sales reaching billions of dollars. In the most recent quarter, the company reported revenue exceeding $3 billion and projects full-year revenue to reach up to $12 billion. In recent years, Vertex has also expanded into other areas to capture new growth, such as its blood disorder drug Casgevy, which exceeded its $100 million revenue target last year, and its novel pain medication Journavx, whose prescriptions are projected to triple this year. With these growth drivers and progress in its R&D pipeline, Vertex possesses multiple positive catalysts that could drive outstanding stock performance by 2030.
